Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE 2 ( March-April, 2024 ) > List of Articles

CASE REPORT

Dilemmas and Difficulties in Dealing with Receptor-positive Breast Cancer Patients Seeking Fertility Care: A Case Report!

Kunur Shah

Keywords : Breast cancer, Case report, Fertility preservation, Oocyte cryopreservation, Oncofertility, Receptor

Citation Information : Shah K. Dilemmas and Difficulties in Dealing with Receptor-positive Breast Cancer Patients Seeking Fertility Care: A Case Report!. J South Asian Feder Obs Gynae 2024; 16 (2):189-191.

DOI: 10.5005/jp-journals-10006-2378

License: CC BY-NC 4.0

Published Online: 23-02-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Aim: Addressing the fertility preservation needs of breast cancer patients with receptor-positive presents considerable dilemmas and difficulties. Case description: Presenting a case of a 35-year-old unmarried female with receptor-positive breast malignancy who was referred for fertility preservation. Counseling regarding remote risk with controlled ovarian stimulation using antagonist protocol was done. Antiestrogen therapy with letrozole was added to minimize the risk with supraphysiologic estrogen levels. Five mature metaphase II (MII) oocytes were retrieved and cryopreserved for future use. Conclusion: Oocyte cryopreservation in unmarried cancer patients is an acceptable option. The addition of antiestrogen-like letrozole is advisable in estrogen receptor-positive cases. Fertility concerns of young patients should be addressed with a multidisciplinary approach.

HTML PDF Share
  1. Donnez J, Dolmans MM. Fertility preservation in women. N Engl J Med 2017;377(17):1657–1665. DOI: 10.1056/NEJMra1614676.
  2. Mahany EB, Hershman DL, Sauer MV, et al. Pregnancy despite ovarian insufficiency in a patient with breast cancer. Reprod Med Biol 2012;12(1):35–38. DOI: 10.1007/s12522-012-0133-x.
  3. European Society of Human Reproduction and Embryology. ESHRE Guideline Female fertility preservation. 2020. Available at: https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Female-fertility-preservation. Accessed on: 7 October 2023.
  4. Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: Does timing of conception affect infant health? Cancer 2018;124(22):4401–4407. DOI: 10.1002/cncr.31732.
  5. Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 2013;31(19):2500–2510. DOI: 10.1200/JCO.2013.49.2678.
  6. Brougham MFH, Crofton PM, Johnson EJ, et al. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: A prospective study. J Clin Endocrinol Metab 2012;97(6):2059–2067. DOI: 10.1210/jc.2011-3180.
  7. Griesinger G, Berndt H, Schultz L, et al. Intensified ovarian stimulation in a GnRH antagonist protocol with agonist triggering: A prospective, clinical feasibility study. Reprod Biomed Online 2011;22(2):133–139. DOI: 10.1016/j.rbmo.2010.10.017.
  8. Starek-Świechowicz B, Budziszewska B, Starek A. Endogenous estrogens—breast cancer and chemoprevention. Pharmacol Rep 2021;73(6):1497–1512. DOI: 10.1007/s43440-021-00317-0.
  9. Sleightholm R, Neilsen BK, Elkhatib S, et al. Percentage of hormone receptor positivity in breast cancer provides prognostic value: A single-institute study. J Clin Med Res 2021;13(1):9–19. DOI: 10.14740/jocmr4398.
  10. Mathiesen RR, Borgen E, Renolen A, et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res 2012;14(4):R117. DOI: 10.1186/bcr3242.
  11. Peters A, Tadi P. Aromatase inhibitors. In: StatPearls. StatPearls Publishing; 2023. Available at: http://www.ncbi.nlm.nih.gov/books/NBK557856/. Accessed on: 10 September 2023.
  12. Bedaiwy MA, Mousa NA, Casper RF. Aromatase inhibitors: Potential reproductive implications. J Minim Invasive Gynecol 2009;16(5): 533–539. DOI: 10.1016/j.jmig.2009.05.009.
  13. Levi-Setti PE, Patrizio P, Scaravelli G. Evolution of human oocyte cryopreservation: Slow freezing versus vitrification. Curr Opin Endocrinol Diabetes Obes 2016;23(6):445–450. DOI: 10.1097/MED.0000000000000289.
  14. Grynberg M, Sonigo C, Santulli P. Fertility preservation in women. N Engl J Med 2018;378(4):400. DOI: 10.1056/NEJMc1715731.
  15. Cobo A, García-Velasco J, Domingo J, et al. Elective and onco-fertility preservation: Factors related to IVF outcomes. Hum Reprod Oxf Engl 2018;33(12):2222–2231. DOI: 10.1093/humrep/dey321.
  16. Goldman KN, Kramer Y, Hodes-Wertz B, et al. Long-term cryopreservation of human oocytes does not increase embryonic aneuploidy. Fertil Steril 2015;103(3):662–668. DOI: 10.1016/j.fertnstert.2014.11.025.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.